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Abstract: 
Background 
Genome-wide association studies of Alzheimer’s disease (AD) have identified a number of 
significant risk loci, the majority of which lie in non-coding regions of the genome. The lack of 
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causal alleles and considerable polygenicity remains a significant barrier to translation into 
mechanistic understanding. This includes identifying causal variants and the cell/tissue types 
in which they operate. A fuller understanding of the cell types and transcriptional networks 
involved in AD genetic risk mechanisms will provide important insights into pathogenesis. 
Methods 
We assessed the significance of the overlap between genome-wide significant AD risk 
variants and sites of open chromatin from data sets representing diverse tissue types. We 
then focussed on macrophages and microglia to investigate the role of open chromatin sites 
containing motifs for specific transcription factors. Partitioned heritability using LDscore 
regression was used to investigate the contribution of specific macrophage and microglia 
transcription factor motif containing open chromatin sites to the heritability of AD. 
Results 
AD risk single nucleotide polymorphisms (SNPs) are preferentially located to sites of open 
chromatin in immune cells, particularly monocytes (z-score = 4.43; corrected P = 5.88x10-3). 
Similar enrichments are observed for macrophages (z-score = 4.10; corrected P < 2.40x10-3) 
and microglia (z-score = 4.34, corrected P = 0.011). In both macrophages and microglia, AD 
risk variants are enriched at a subset of open chromatin sites that contain DNA binding 
motifs for specific transcription factors e.g. SPI1 and MEF2. Genetic variation at many of 
these motif containing sites also mediate a substantial proportion of AD heritability, with SPI1 
containing sites capturing the majority of the common variant SNP-chip heritability (microglia 
enrichment = 16.28, corrected enrichment P = 0.0044). 
Conclusions 
AD risk alleles plausibly operate in immune cells, including microglia, and are concentrated 
in specific transcriptional networks. Combined with primary genetic association results, SPI1 
and MEF2 transcriptional networks appear central to AD risk mechanisms. Investigation of 
transcription factors targeting AD risk SNP associated regulatory elements could provide 
powerful insights into the molecular processes affected by AD polygenic risk. More broadly, 
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our findings support a model of polygenic disease risk that arises from variants located in 
specific transcriptional networks.  
Key words: Alzheimer’s disease, GWAS, transcription factor, non-coding variation. 
 
Background: Genome-wide association studies (GWAS) of AD have identified multiple loci 
containing common variant risk alleles[1]. These findings offer new routes to understanding 
disease biology that could be used to design novel therapies. However, like other complex 
diseases and traits, the majority of these risk alleles are located in non-coding regions of the 
genome[2] making immediate functional interpretation difficult. Furthermore, at each locus 
the risk signal is often associated with multiple variants in strong linkage disequilibrium (LD), 
any of which could credibly be the causal variant(s).  Nevertheless, analytical approaches 
such as pathway analysis[3] and integration with chromatin annotations[4, 5] have begun to 
identify the cell types and processes that are likely to be disrupted by AD risk alleles. 
Strikingly, these complimentary approaches have identified immune cells and pathways as 
the likely effectors of AD genetic risk. Despite these advances, the full repertoire of 
potentially causal cell types and the molecular mechanisms through which AD risk variants 
operate have yet to be fully investigated. This includes the identification of functional variants 
at genome-wide significant risk loci as well as the mechanisms through which polygenic risk 
operates. 
Of these approaches, integration of genetic association data with the growing amount of 
functional genomic annotations (e.g. ENCODE[6] and Roadmap Epigenomics[7]) have the 
potential to identify: (1) causal non-coding risk alleles; (2) the mechanisms by which they 
operate; and (3) the cell types in which they function[8, 9]. While risk alleles at genome-wide 
significant loci represent robust findings suitable for biological characterisation, it is now 
known that thousands of variants throughout the genome contribute to disease 
heritability[10]. Recently developed analytical methods, such as stratified LDscore 
regression[11, 12], can use these annotations to investigate the relevance of specific cell 
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types to the heritability of a disease of interest, extending analysis beyond genome-wide 
significant loci to capture polygenic risk mechanisms.  
Several technologies now exist for genome-wide identification of non-coding elements with 
regulatory potential. These range from the study of post-translational modifications of 
histones to the resolution of binding sites for specific transcription factors; collectively termed 
chromatin immunoprecipitation (ChIP). Methods that rely on discriminating local chromatin 
structure such as DNase-seq[13] and Assay for Transposase-Accessible Chromatin using 
sequencing (ATAC-seq)[14] can identify potential transcription factor binding sites without 
the need for performing multiple transcription factor ChIP experiments. These open 
chromatin regions (OCRs) display a high degree of cell type specificity, defining promoters of 
expressed genes as well as distal regulatory elements[13], and are enriched for DNA motifs 
recognised by transcription factors important for determining cell lineage and function[15]. 
Although the integration of chromatin annotations with GWAS results has been successful in 
identifying disease relevant tissues[2, 8, 16] few, if any, have attempted to attribute genome-
wide polygenic risk mechanisms to specific transcription factor networks. 
We therefore reasoned that the integration of results from genome-wide association studies 
of AD with OCRs from multiple cell types would pinpoint disease relevant cell types and link 
AD genetic risk variants to specific transcriptional networks active in those cell types 
 
 
Methods: 
Data processing 
DNase hypersensitivity sites (DHSs) and histone ChIP-seq peaks (H3K4me3, H3K4me1 and 
H3K27ac) were generated by the Roadmap Epigenomics Project[7]. Monocyte and 
macrophage DNase-seq data was generated by BLUEPRINT (http://dcc.blueprint-
epigenome.eu/#/home). All data sets had been mapped to hg19 (GRCh37). Data were 
processed using BEDTools [27]. Cancer derived cells lines present in the Epigenomics 
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Roadmap data set were removed before further analyses. Microglia ATAC-seq data[17] was 
obtained from dbGaP Study Accession: phs001373.v1.p1. Data were aligned to hg19 
(GRCh37) using bwa[18] and peaks called using hotspot[19], following the protocol 
described by the BLUEPRINT consortium.  
Enrichment testing for the overlap between AD risk variants and open chromatin 
regions 
Genome-wide significant (P < 5 x 10-8) AD risk variants (GWAS index SNPs) identified by 
Lambert et al[1] were downloaded from the GWAS catalogue[20]. Variants located in the 
APOE and major histocompatibility complex (MHC) regions were excluded, resulting in 18 
GWAS index SNPs. For the remaining GWAS index SNPs, 10,000 matched sets of variants 
were generated using SNPsnap[21], which matches SNPs based on allele frequency, 
number of SNPs in LD, distance to nearest gene and gene density. Variants in high LD (r2 > 
0.8) with each SNP (GWAS index SNPs and matched sets) were extracted from 1000 
genomes project (phase 3). The resulting 10,001 SNP sets were then intersected with OCRs 
and histone peaks using BEDTools. The number of overlapping loci was calculated for each 
set and the deviation from the background matched sets was calculated as a z-score. P 
values were calculated by direct observation of the number of background matched SNPs 
sets that exceeded the overlap of the GWAS index SNP set (minimum possible uncorrected 
P value is therefore 1 x 10-4).  
De novo motif analysis and assignment to open chromatin regions 
Macrophage DHSs for the 16 data sets from the BLUEPRINT project were merged to form a 
consolidated data set using BEDTools, run with default parameters. Microglia ATAC peaks 
for the 12 donors were similarly merged to form a consolidated set. The consolidated sets 
were then used as input for de novo motif discovery using HOMER[22] with default 
parameters. The resulting motifs were then assigned to OCRs using the HOMER command 
findMotifs.pl with the ‘-find’ option enabled.  
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Partitioned heritability using LDscore regression 
LDscore regression[11,12] was used to partition AD genetic heritability by motif containing 
sites identified as being enriched at genome-wide significant loci (e.g. CEBPA, EGR1, 
MEF2A and SPI1 for macrophages), following previously described methodology[12]. 
Alzheimer’s disease genome-wide associated results were downloaded from 
http://web.pasteur-lille.fr/en/recherche/u744/igap/igap_download.php, and only phase 1 data 
was used. The no motif containing set was included as a negative control. Sites were 
extended by +/- 500 base pairs, consistent with previous partitioning heritability studies[12]. 
LDscore files were made for each specific annotation of interest using the open source 
software available here: https://github.com/bulik/ldsc/wiki. The MHC region (chr6:26,000-
34,000kb) and APOE region (chr19:44,400-46,500kb) were removed. The results remain 
significant with the inclusion of these regions (data not shown). Each annotation was added 
to the baseline model independently creating 5 separate models. The baseline model 
includes 24 non-cell specific annotations that cover a range of DNA features, such as 
coding, three prime untranslated region, promoter, intronic, H3K4me1 marks, H3K4me3 
marks, H3K9ac marks, H3K27ac marks, DNase I hypersensitivity sites, chromHMM and 
Segway predictions, regions conserved in mammals, super-enhancers, and FANTOM5 
enhancers (please see Finucane et al[12] for more information about the baseline model).  
Web resources: 
Software: 
Ldscore: https://github.com/bulik/ldsc/wiki 
HOMER: http://homer.ucsd.edu/homer/motif/index.html 
SNPsnap: https://data.broadinstitute.org/mpg/snpsnap/ 
BEDTools: http://bedtools.readthedocs.io/en/latest/ 
Data availability: 
Data generated by the Roadmap Epigenomics Project were downloaded from 
http://egg2.wustl.edu/roadmap/data/byFileType/peaks/consolidated/broadPeak/Dnase/   
http://egg2.wustl.edu/roadmap/data/byFileType/peaks/consolidated/broadPeak/ 
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http://egg2.wustl.edu/roadmap/data/byFileType/peaks/consolidated/narrowPeak/ 
BLUEPRINT monocyte and macrophage DHSs were downloaded from 
http://ftp.ebi.ac.uk/pub/databases/blueprint/data/homo_sapiens/GRCh37/ 
Alzheimer’s disease genome-wide associated results were downloaded from 
http://web.pasteur-lille.fr/en/recherche/u744/igap/igap_download.php  
1000Genomes data was downloaded from 
http://www.internationalgenome.org/about#ProjectSamples  
Microglia ATAC-seq data was obtained from: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-
bin/study.cgi?study_id=phs001373.v1.p1  
Results: 
Enrichment of AD risk variants at DNase hypersensitivity sites (DHSs) across 
tissue/cell types 
We assessed whether AD risk variants (index SNPs and variants in LD at r2 > 0.8) were 
preferentially located to DHSs from a panel of 38 tissues profiled by the Roadmap 
Epigenomics consortium[7]. Three cell/tissue types remained significant after correcting for 
all tests of enrichment (DNase and the three histone modifications)  using the method 
described in Benjamini & Hochberg[23] (Figure 1). Of these, two were immune cell types 
(‘primary hematopoietic stem cells G-CSF-mobilized’, z-score = 4.75, corrected P = 4.2x10-3; 
and ‘primary monocytes from peripheral blood’, z-score 4.43, corrected P = 5.9x10-3). 
Several other immune cell types ranked highly in the analysis with 4 of the 5 most enriched 
tissue types being immune cells, however these did not remain significant after correction for 
multiple testing. Only two brain samples, both foetal, were available in this DHS data set, 
and neither showed significant enrichment after correction for multiple testing (z-score = 2.63 
and 1.40, uncorrected P = 0.011 and 0.140). Full details of the results for each sample can 
be found in Additional file 1: Table S1. To confirm our cell/tissue type enrichments, we also 
performed enrichment analyses using regions marked by the histone modifications 
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H3K27ac, H3K4me1 and H4K3me3. For all three histone modifications the largest 
enrichment was observed in monocytes (Additional file 2: Table S2; Additional file 3: Table 
S3; Additional file 4: Table S4).Although several immune cell types were significantly 
enriched across these analyses, only monocytes were significant in all four chromatin 
feature analyses. 
Enrichment of AD risk variants at DNase hypersensitive sites in monocytes and 
macrophages. 
Given that data generated from the Roadmap Epigenomics consortium are derived from a 
limited number of donors, we sought to replicate these findings and test additional immune 
cell types. DNase hypersensitivity data from 16 macrophage and 7 monocyte samples were 
available from the BLUEPRINT epigenome project (http://dcc.blueprint-
epigenome.eu/#/home). Using these data, enrichment z-scores for the overlap with AD risk 
variants ranged from 3.00 to 5.07 (mean = 4.12) for the 7 monocyte samples, and 1.98 to 
5.32 (mean = 3.88) for the 16 macrophage samples (Figure 2). In total, 14 of the 23 samples 
tested were significant after correction for multiple testing using the Bonferroni method to 
correct for 37 tests (35 monocyte/macrophage/microglia samples plus the two consolidated 
sets), replicating the enrichment of AD variants at immune cell DHSs, and identifying 
macrophages as a potential cell type affected by AD genetic risk. 
To reduce inconsistencies arising from selecting individual donor samples, a consolidated 
set of macrophage DHSs was generated by merging the peaks from the 16 different data 
files. AD risk variants were similarly enriched at DHSs in this consolidated set (z-score = 
4.10, P < 1 x 10-4, corrected P < 3.7x10-3), with 13 of the 18 loci tested having at least one 
overlapping SNP (Figure 3). At these 13 loci, the number of SNPs overlapping macrophage 
DHSs ranges from 1 to 11 (Additional file 5: Table S5 and Additional file 6: Figure S1), 
indicating multiple potential causal alleles. These loci contain genes both with overt immune 
cell functions (e.g. INPP5D) and those with no known immune cell specific activity (e.g. BIN1 
and PICALM).   
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Enrichment of AD risk variants at open chromatin regions in microglia 
We obtained publically available human microglia open chromatin (ATAC-seq) data from 12 
donors[17] to investigate the role of the resident brain macrophage in AD genetic risk 
mechanisms. We observed enrichment z scores ranging from 2.77 - 5.25 (mean = 4.07). In 
total, 9 donor samples were significant after Bonferroni correction for the 37 tests (35 
monocyte/macrophage/microglia samples plus the two consolidated sets). AD risk variants 
were also enriched at microglia ATAC-seq peaks using the consolidated peak set (z-score = 
4.34, corrected P = 0.011), with a total of 11 loci containing at least one SNP that overlapped 
an ATAC-seq peak (Figure 3). Additional file 7: Table S6 contains a full list of overlapping 
SNPs and gene annotations.  
Enrichment of AD risk SNPs at open chromatin regions containing specific 
transcription factor motifs 
We further investigated the localisation of AD risk variants to specific subsets of macrophage 
and microglia OCRs defined by the presence of specific transcription factor DNA binding 
motifs. De novo motif analysis of the consolidated sets of macrophage DHS or microglia 
ATAC-seq peaks was performed using HOMER[22].  
In macrophages DHS, this identified 15 enriched motifs (Additional file 8: Table S7), 
including established regulators of immune cell function (e.g. SPI1 and NFKB). We then 
grouped DHSs according to the presence or absence of a motif for each of the 15 motifs 
identified, generating 16 subsets, one for each specific transcription factor motif and one with 
DHSs that lacked any of these motifs. Two motif sets were removed from the analysis as 
fewer than 1000 of the 10,000 background matched SNPs set showed any overlap. AD risk 
variants were significantly enriched after correction for multiple testing using Bonferroni 
method at DHSs containing SPI1 (PU.1) (z-score = 5.53, corrected P < 1.30x10-3), EGR1 (z-
score = 4.40, corrected P < 1.30x10-3), MEF2A (z-score = 4.08, corrected P = 0.023) or 
CEBPA (z-score = 3.68, corrected P = 0.013) motifs (Figure 4A). The SPI1 (PU.1) motif set 
captured all 13 of the loci that showed overlap with the consolidated macrophage DHS set. 
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The number of SNPs overlapping SPI1 motif containing DHS at each locus ranged from 1 to 
7, implicating multiple potential causal SNPs.  
De novo motif analysis of the microglia ATAC-seq peaks identified 19 motifs (Additional file 
9: Table S8), including known lineage determining factors such as SPI1 and IRF[24]. Sets of 
motif containing peaks were then generated as described above. After intersecting with SNP 
data, one motif set was removed from the analysis as fewer than 1000 of the 10,000 
background matched SNPs set showed any overlap. AD risk variants were significantly 
enriched at ATAC-seq peaks containing motifs for RUNX (z-score = 5.22, corrected P < 1.9 
x 10-3), SPI1 (PU.1) (z-score = 5.02, corrected P < 1.9 x 10-3), Spdef (z-score = 3.80, 
corrected P = 0.027) after correction for multiple testing using Bonferroni method (Figure 
4B). Similar to the macrophages, the SPI1 (PU.1) set captured the largest number of loci, 
accounting for 9 of the 11 overlaps identified using all ATAC-seq peaks in the consolidated 
set. We validated our motif based findings using SPI1 (PU.1) ChIP-seq data from human 
microglia[17]. AD risk variants were significantly enriched at these experimentally identified 
SPI1 (PU.1) bound regions (z-score = 4.62, P =2x10-4; Additional file 6: Figure S2).  
For both macrophages and microglia, SPI1 (PU.1) motif containing OCRs were significantly 
enriched, indicating that this class of OCR is of relevance to AD genetic risk mechanisms in 
both cell types. CEBP and MEF2 motif containing OCRs survived correction for multiple 
testing in macrophages, and were nominally significant (uncorrected P <0.05) in microglia. 
Several motif containing OCR sets were only tested in one cell type as de novo motif 
analysis did not identify them in the other, e.g. EGR1 for macrophages and RUNX for 
microglia.  
Common variant heritability of AD is enriched at specific transcription factor motif 
containing open chromatin regions.  
Although many genome-wide significant AD risk loci have been identified, they account for a 
small proportion of the genetic heritability. Instead 1000s of variants across the entire 
genome collectively contribute to the polygenic inheritance of AD. We reasoned that 
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transcription factor motif containing OCRs identified as being enriched at genome-wide 
significant loci would also be important for mediating polygenic inheritance. Therefore, we 
partitioned AD heritability by macrophage or microglia motif sets using LDscore 
regression[12].  
Consistent with the macrophage SNP enrichment analysis of genome-wide significant loci, 
AD heritability was significantly enriched at variants in SPI1 (PU.1) (enrichment = 8.93, 
corrected enrichment P = 0.012), MEF2A (enrichment = 19.22, corrected enrichment P 
=0.022), CEPBA (enrichment = 9.72, corrected enrichment P = 3.43x10-3) and EGR1 
(enrichment = 14.48, corrected enrichment P = 5.14x10-4) DHS motif sets. P-values for all 
the transcription factors tested withstood Bonferroni correction for multiple testing (Table 1). 
Importantly, the ‘no motif’ DHS set was not significantly enriched (corrected enrichment P = 
0.625) (Table 1). Full results table included as Additional file 10: Table S9. 
In microglia, AD heritability was significantly enriched at variants in SPI1 (PU.1) (enrichment 
= 16.28, corrected enrichment P = 4.39x10-3) and Spdef (enrichment = 19.92, corrected 
enrichment P = 0.040) OCR motif sets. The RUNX OCR motif set was not significantly 
enriched (enrichment = 14.09, correct enrichment P = 0.412), nor was the ‘no motif’ set 
(enrichment = 20.27, corrected enrichment P = 0.168). P-values were corrected using 
Bonferroni correction for multiple testing accounting for the number of tests undertaken 
within each cell type (Table 2). Full results table included as Additional file 11: Table S10. 
The enrichment of AD heritability at variants in SPI1 motif containing OCRs was validated 
using the SPI1 ChIP-seq data. Variants at these SPI1 bound regions were also substantially 
enriched for AD heritability (enrichment = 20.56, enrichment P = 6.9x10-4) 
Discussion 
Although GWAS have identified thousands of variants that influence diseases and traits, the 
majority are located in non-coding regions of the genome[2]. Combined with small effect 
sizes, the biological interpretation of these results is challenging. We have integrated results 
from GWAS of AD with open chromatin regions identified in different tissue types, first by 
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using genome-wide significant loci and then extending our analyses to genome-wide 
measurements of partitioned heritability. Through this two stage approach, we identify alleles 
of potential functional significance that are amenable to further mechanistic investigation, 
and show variants contributing to polygenic inheritance are likely to operate through shared 
mechanisms. Specifically, these analyses identified macrophage and microglia 
transcriptional networks in which both genome-wide significant alleles and polygenic risk for 
AD are enriched.   
Localisation of AD risk variants to DHSs from multiple immune cell types assayed by the 
Epigenomics Roadmap Project highlights their potential importance in mediating the effects 
of AD genetic risk, and is in agreement with other studies[4, 5]. Our analyses using histone 
modifications indicative of active gene regulatory elements also strongly supports the role of 
immune cells, particularly monocytes, in AD genetic risk mechanisms. Enrichment at all 
three histone modifications tested suggests risk mechanisms involve multiple types of 
regulatory elements (e.g. promoters and enhancers). Combined with results generated using 
data from the BLUEPRINT Epigenome project, we provide replicated evidence for the 
enrichment of AD risk variants at monocyte DHSs. A similar enrichment is also observed at 
macrophage DHSs, a cell type derived from monocytes that have invaded a target tissue. 
Finally, we show that microglia are also plausibly linked to AD genetic risk mechanisms via 
regions of open chromatin. Unlike studies of post-mortem material, where cause cannot 
easily be separated from consequence, genetics associations do not suffer from problems of 
reverse causation, therefore our findings implicate immune cell dysfunction as a causal 
factor in AD risk. Given the extensive overlap between regulatory elements in related cell 
types, it is not currently possible to identify a single causal immune cell type and we cannot 
excluded the involvement of multiple cell types in AD risk mechanisms. However, the 
location of microglia to the brain positions them as the likely causal candidates.   
In contrast to the significant enrichment at immune cell DHSs, AD risk variants were not 
enriched at brain DHSs identified using bulk tissue. However, DHSs data from the 
Epigenomics Roadmap project contains only two brain samples, both foetal. The enrichment 
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at microglial OCRs suggests that they are the plausible brain cell type in which AD risk 
mechanisms operate, and that profiles from bulk tissue suffer from lack of cell type 
specificity. It will be necessary to investigate additional brain data as it becomes available, 
particularly those that can resolve cell type specific information[25].It should also be noted 
that currently available data are primarily derived from healthy donors under basal 
conditions. To fully investigate the gene regulatory mechanisms underlying genetic disease 
risk, it will be necessary to investigate cells under a variety of conditions, including those 
thought to be environmental risk factors for disease.  
Consistent with gene based pathway analysis of AD GWAS[26, 27], these loci harbour 
genes such as PTK2B and INPP5D that encode for proteins with recognised immune 
functions and have immune cell type enriched expression. However, it is at the level of DNA 
regulatory elements that tissue specific risk mechanisms are generated. Indeed, our analysis 
identifies a number of ubiquitously expressed genes (e.g. BIN1 and CD2AP) at which AD 
associated risk variation could credibly operate in immune cells, including microglia. 
Therefore, the number of AD risk loci that impact on immune cell function is likely to be 
larger than that captured by current gene based pathway annotation methods. It will now be 
important to identify the biological processes that are disrupted by AD risk variants in 
immune cells.  
Of the 18 genome-wide significant loci tested, 13 have at least one variant located in a 
macrophage DHS and 11 in a microglial OCR indicating that the majority of AD risk loci 
plausibly operate to alter gene expression in these cells. At most of these loci more than one 
SNP overlapped an OCR, suggesting that individual risk loci are likely to harbour multiple 
functional variants. By focusing on OCRs containing transcription factor motifs, the number 
of overlapping SNPs at each locus is reduced; e.g. in microglia 8 of the 11 loci contain 3 or 
fewer SNPs overlapping a SPI1 motif containing OCRs. These variants can therefore be 
prioritised for further molecular characterisation. 
Having established an enrichment of AD risk variants at macrophage and microglia OCRs, 
we investigated their localisation to OCRs containing motifs for specific transcription factors. 
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Within a given cell type thousands of transcriptional regulators contribute to the control of 
gene expression, but master regulators, often cell type specific, can be recovered by motif 
analysis of regulatory element sequences. In both macrophage and microglia, AD risk 
variants were enriched at OCRs containing specific transcription factor motifs, supporting the 
hypothesis that risk variants are localised to specific transcription factor targeted OCRs, 
including experimentally determined SPI1 bound regions in microglia.  
Of particular interest is the enrichment of AD risk SNPs at SPI1 and MEF2A motif containing 
OCRs. Genetic variants at, or in close proximity to, SPI1 and MEF2C (HOMER reports that 
the MEF2C and MEF2A motifs have a similarity score of 0.94) have been identified as 
significant AD risk loci[1, 28]. Impaired transcriptional control by these factors, either through 
altered gene expression in cis, or via disrupted DNA binding due to genetic variants at target 
sites is likely to play a central role in AD genetic risk mechanisms. The importance of 
variants in these motif containing OCRs extends beyond those reaching genome-wide 
significance, providing evidence that the thousands of subthreshold variants contributing to 
polygenic risk collectively operate by similar mechanisms. Although enrichment at these 
sites is large (~9-19 fold), and account for a substantial proportion of the total SNP-chip 
heritability, the p-values reported are weaker than those observed in analyses of some other 
diseases using chromatin features[12]. This is most likely due to the low SNP-chip heritability 
of AD as calculated by LDscore regression (~7%, http://ldsc.broadinstitute.org/lookup/). 
GWAS data from larger cohorts will be important for defining risk mechanisms at increased 
molecular resolution. Similarly, the identification of transcription factor motifs from studies of 
open chromatin derived from additional methods will reduce potential single source biases. 
More generally, our results support a model of polygenic disease risk that is enriched at 
defined transcriptional networks operating in cell types relevant to disease. For other 
complex disorders such as type 2 diabetes, genome-wide significant risk variants have been 
shown to localise to specific transcription factor binding sites in islet cells[29, 30], but the 
extent to which variants in these binding sites contribute to polygenic inheritance was not 
investigated. We show that polygenic risk arising from non-coding variation is localised to 
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specific transcription factor networks. For AD this is most prominent for a potential SPI1 
driven network, consistent with a targeted investigation [31]. 
SPI1 encodes a transcription factor known to be critical for the development and function of 
hematopoietic cell lineages[32], including microglia[24]. Decreased expression of SPI1 and 
CEBPA (also identified through motif enrichment analysis in macrophages) is observed after 
reduction in AD like pathology and behaviour in APPswe/PSEN1dE9 mice following 
pharmacological inhibition of the receptor CSF1R[33]. Therefore, our results link polygenic 
AD risk mechanisms to transcriptional networks that have therapeutic validity. The 
identification of upstream regulators of these transcription factors may yield novel targets 
important for AD therapies.  
Conclusions 
In summary, integration of GWAS results with sites of open chromatin identifies immune 
cells as likely mediators of common variant genetic risk for AD. The majority of genome-wide 
significant AD risk loci plausibly operate in peripheral monocytes, macrophages and/or 
microglia, and we identify candidate SNPs at these loci suitable for targeted mechanistic 
studies based on shared OCR annotations. Within open chromatin sites, those containing 
specific DNA motifs drive this enrichment. Similarly, genetic variants at these sites capture a 
substantial proportion of the AD common variant SNP-chip heritability, ~67% for the SPI1 
targeted sites, increasing the molecular resolution of AD genetic risk mechanisms from cell 
type to transcriptional networks. We provide evidence for the causal role of microglia in AD 
pathogenesis and therefore a parsimonious explanation for the involvement of immune cells 
in AD risk mechanisms. Furthermore, we establish that the thousands of variants 
contributing to AD polygenic risk are enriched at specific macrophage/microglial 
transcriptional networks, placing them in tangible biological pathways amenable to future 
mechanistic studies. 
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Table 1.  
Enrichment of AD heritability at variants within EGR1, CEBPA, MEF2A, SPI1 and ‘no 
motif’ containing macrophage DNase hypersensitivity sites.  
DHS motif set Enrichment Enrichment 
P-value 
Corrected  
P-value 
EGR1 14.481 1.03x10-4 5.14x10-4 
CEBPA 9.716 6.86x10-4 3.43x10-3 
SPI1 8.933 2.43x10-3 0.012 
MEF2A 19.222 4.46x10-3 0.022 
No motif 7.661 0.125 0.623 
AD heritability was partitioned by transcription factor motif containing DNase 
hypersensitivity sites using LDscore regression[12]. AD heritability was significantly 
enriched (after correcting for multiple testing) at all four transcription factor motif 
containing DNase hypersensitivity sites but not the ‘no motif’ set. 
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Table 2.  
Enrichment of AD heritability at variants within SPI1, Spdef, RUNX and ‘no motif’ 
containing microglia ATAC-seq peaks.  
Motif set Enrichment Enrichment 
P-value 
Corrected  
P-value 
SPI1 16.28 1.10x10-3 4.39x10-3 
Spdef 19.92 9.93x10-3 0.040 
No motif 20.27 0.042 0.168 
RUNX 14.09 0.103 0.412 
AD heritability was partitioned by transcription factor motif containing ATAC-seq peaks 
using LDscore regression[12]. AD heritability was significantly enriched (after correcting 
for multiple testing) at SPI1 and Spdef transcription factor motif containing ATAC-seq 
peaks but not the RUNX or ‘no motif’ sets. 
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Figure Legends 
 
Figure 1.  (Colour figure in print) 
Overlap between genome-wide significant AD risk variants and DNase 
hypersensitivity sites from 38 tissues profiled by the Roadmap Epigenomics Project. 
AD risk variants and 10,000 sets of matched SNPs were intersected with DNase 
hypersensitivity sites. Z-scores were calculated for the AD risk variants set for each tissue 
type. X axis is the z-score and the Y axis the tissue types. Box plots indicate the distribution 
of overlap from the 10,000 background matched SNP sets. Tissue have been coded as 
blood (red), brain (green) and other (blue). Red circles are the z-scores for the AD risk 
variants set. P values were calculated from the observed overlap of the 10,000 background 
matched SNP sets. P values are corrected using the method described in Benjamini & 
Hochberg[23]. *** P < 0.005, ** P < 0.01.  
 
Figure 2.  (Colour figure in print) 
Overlap between genome-wide significant AD risk variants and open chromatin sites 
identified in monocyte, macrophage and microglia samples. AD risk variants and 10,000 
sets of matched SNPs were intersected with open chromatin regions. Z-scores were 
calculated for the AD risk variants set for each tissue type. X axis is the z-score and the Y 
axis the cell type. Box plots indicate the distribution of overlap from the 10,000 background 
matched SNP sets. Red circles are the z-scores for the AD risk variants set. P values were 
calculated from the observed overlap of the 10,000 background matched SNP sets. P values 
have been corrected for 37 tests. *** P < 0.005, ** P < 0.01, * P < 0.05.  
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Figure 3.  
Overlap between genome-wide significant AD risk variants and open chromatin 
regions from the consolidated set of macrophage/microglia samples. Grey histogram 
bars are the distribution of overlap from the 10,000 background matched SNP sets. The 
vertical black line is the number of overlapping loci from the AD risk variants set.  
 
Figure 4.  
Overlap between genome-wide significant AD risk variants and transcription factor 
motif containing open chromatin sites from the consolidated macrophage (A) and 
microglia (B) data. AD risk variants and 10,000 sets of matched SNPs were intersected 
with transcription factor motif containing open chromatin region sets and one no motif 
containing set for each cell type. X axis is the z-score and the Y axis is the transcription 
factor motif. Box plots indicate the distribution of overlap from the 10,000 background 
matched SNP sets. Red circles are the z scores for the AD risk variants set. P values were 
calculated from the observed overlap of the 10,000 background matched sets.  P values 
have been adjusted within each cell type using Bonferroni correction for the number of motif 
sets tested*** P < 0.005, * P < 0.05.  
 
